Gamida Cell Ltd. (GMDA) Prices 13.334M Share Common Offering at $4.50/Sh

Gamida Cell Ltd. (NASDAQ: GMDA) today announced the pricing of an underwritten public offering of 13,333,334 ordinary shares at a public offering price of $4.50 per share for aggregate gross proceeds of approximately $60 million, before deducting underwriting discounts and commissions and estimated offering expenses. In addition, Gamida Cell has granted the underwriters a 30-day option to purchase up to an additional 2,000,000 ordinary shares at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on or about May 21, 2020, subject to satisfaction of customary closing conditions.

Gamida Cell intends to use the net proceeds from this offering, together with its existing cash and cash equivalents, available for sale and short-term deposits: to fund (i) the preparation of a Biologics Licensing Application for omidubicel in high-risk hematologic malignancies; (ii) the continued clinical development of its product candidates; (iii) the expansion of its commercial manufacturing capabilities; and (iv) general corporate purposes, including general and administrative expenses and working capital.

Piper Sandler & Co. and Evercore Group L.L.C. are acting as joint book-running managers for this offering. JMP Securities LLC is acting as lead manager for this offering.

You May Also Be Interested In

• Robo.ai Inc (AIIO) files for 22.34M share offering by selling stockholders
• Sinda Ltd. prices IPO at $12 per share on NYSE
• Tianci International updates Zimbabwe gold and chromium project progress